SCHEDULE: Armistice Capital Reports 9.99% Stake in Estrella Immunopharma

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 9.99% of Estrella Immunopharma, Inc.'s common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, indicating their beneficial ownership of 4,280,375 shares of Estrella Immunopharma, Inc. common stock.
• This holding represents 9.99% of the class of securities.
• Armistice Capital, LLC is the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It indicates a significant investment stake but provides no operational or financial performance data for Estrella Immunopharma, Inc.

Positives

• Significant stake reported by a known investment manager, potentially indicating confidence in the company's future.
• The filing confirms the shares are held in the ordinary course of business, suggesting a standard investment strategy rather than a hostile takeover attempt.

Negatives

• The filing does not contain financial performance data or operational updates, making it difficult to assess the company's current health.
• The Master Fund disclaims beneficial ownership due to the investment management agreement, which could imply a complex ownership structure.

Risks

• Potential for increased market activity or volatility if Armistice Capital decides to alter its stake.
• The lack of detailed operational or financial information in this filing necessitates further investigation into the company's performance.

Future Outlook

This filing is primarily a disclosure of ownership and does not contain forward-looking statements or financial guidance from Estrella Immunopharma, Inc.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Armistice Capital's strategic interest in Estrella Immunopharma, Inc., a biotechnology company, which is a sector often subject to substantial investment activity.

Stakeholder Impact

• Shareholders: May view the increased stake by Armistice Capital as a positive sign of institutional interest, but the lack of company performance data limits immediate impact assessment.
• Management: May need to engage with Armistice Capital regarding their investment strategy and the company's future direction.

Next Steps

• Monitor future filings from Armistice Capital and Estrella Immunopharma, Inc. for any changes in ownership or strategic developments.
• Further research into Estrella Immunopharma's business operations and financial health is recommended to understand the context of this investment.

Key Dates

Keywords

Schedule 13G, Armistice Capital, Estrella Immunopharma, Beneficial Ownership, Common Stock, Investment Management, SEC Filing